home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9407a.zip
/
M9470049.TXT
< prev
next >
Wrap
Text File
|
1994-07-02
|
2KB
|
29 lines
Document 0049
DOCN M9470049
TI Birth outcomes following zidovudine therapy in pregnant women.
DT 9409
SO MMWR Morb Mortal Wkly Rep. 1994 Jun 10;43(22):409, 415-6. Unique
Identifier : AIDSLINE MED/94254774
AB Approximately 100,000 childbearing-aged women in the United States are
infected with human immunodeficiency virus (HIV), and an estimated 7000
infants are born to HIV-positive mothers each year. In the United
States, the rate of perinatal transmission of HIV among mothers who do
not receive antiretroviral therapy is 15%-30%. Results from a recent
multicenter randomized double-blind clinical trial suggest that
treatment of HIV-positive mothers and their infants with zidovudine
(ZDV) may substantially reduce the risk for perinatal HIV transmission.
However, any potential risk for adverse outcomes associated with use of
antiretrovirals during pregnancy should be considered. This report
summarizes data from the Antiretroviral Pregnancy Registry regarding use
of ZDV and the occurrence of structural birth defects reported for
pregnancies registered during January 1989-December 1993.
DE *Abnormalities, Drug-Induced Female Human HIV Infections/*DRUG
THERAPY/TRANSMISSION Infant, Newborn Pregnancy Pregnancy
Complications, Infectious/*DRUG THERAPY Pregnancy Outcome *Prenatal
Exposure Delayed Effects Registries Zidovudine/*ADVERSE
EFFECTS/THERAPEUTIC USE JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).